EZH2 and nonpapillary renal cell carcinoma: Because tazemetostat is a potent inhibitor of EZH2 [21], its sensitivities to ccRCC (Caki‐1), pRCC (ACHN), and chRCC (UOK‐276) cell lines were assessed.